Agoracom Blog Home

Posts Tagged ‘CBD’

« Older Entries
Newer Entries »

Empower $CBDT.ca Signs Multi-Year Multi-National Licensing Deal with EuroLife $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 4:18 PM on Thursday, February 13th, 2020
  • Empower Clinics to license online education technology to provide strategic value to their patients, retail locations, and to their expanding network of franchisees.

VANCOUVER BC / February 13, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company is pleased to announce it has signed a letter of intent (the “LOI”) with EuroLife Brands Inc. (EURO) (3CMA) (EURPF) (“EuroLife”), a vertically integrated enterprise focused on the pan-European hemp, cannabinoid, and health and wellness sector, granting Empower an exclusive license of EURO’s “Cannvas.me” cloud based online educational platform in certain jurisdictions. The education technology is to be accessed by employees of Empower’s owned and franchised clinics, patients, and a network of nationwide retailers in the United States.

Under the terms of the LOI, Empower will be granted an exclusive license of the Cannvas.me platform in the United States and Mexico (expandable to other jurisdictions). It is envisioned that Empower will integrate and leverage the robust Cannvas.me platform with its burgeoning clinic network across the continental United States. The LOI contemplates a three-year term with a three-year renewable option. An annual $70,000.00 CAD licensing fee will be paid for the life of the proposed agreement, and the issuance of $250,000.00 CAD of Empower common stock at a price of $0.10 per share.

“This next phase in our partnership with Euro is the culmination of many months of collaboration to create access to the immense amount of educational content on the Cannvas.me platform.” said Steven McAuley, Chairman & CEO of Empower. “Empower, as thought leaders in the medical cannabis sector, need to lead consumer & physician education providing a branded curated experience starting with our 165,000 patients and then extending through our network of corporate and franchised clinics.”

“EuroLife’s SaaS based education technology platform will allow Empower Clinics to educate a consumer, retailer, and medical patient on an incredibly efficient basis,” said Shawn Moniz, Chief Executive Officer, EuroLife Brands Inc. “We look forward to working with Empower and their expanding clinic network in providing unencumbered access to our online technology solution.”

In 2018 EuroLife launched a consumer education portal for medical and recreational cannabis consumers. Through many discussions with industry stakeholders the management team discovered there was significant demand for a cloud-based education portal for licensed producers, retail dispensaries and other large to mid-sized companies in the cannabis sector. Executing on a renewed B2B technology model EuroLife recently delivered a redesigned budtender education portal for Aphria Inc. (see February 4, 2020 news release), the global cannabis leader with an unrelenting commitment to people, product quality and innovation. The portal allows Aphria to ensure retail employees across Canada are well-versed in Aphria’s line-up of adult-use brands and enabled with information to provide superior customer service.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.

About EuroLife Brands Inc.

EuroLife Brands (CSE: EURO) (FSE: 3CMA) (OTCPK: EURPF) is a leading global markets cannabis brand empowering the medical, recreational and CPG cannabis industry worldwide through a data-driven CBD marketplace supported by exclusive and unbiased physician-backed cannabis education and detailed consumer analytics.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower $CBDT.ca Signs Multi-Year Multi-National Licensing Deal with EuroLife $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Empower Clinics $CBDT.ca Subsidiary Sun Valley Health to Lead Sponsor the Arizona #Cannabis Expo and Empower Board Member Andrejs Bunkse to Speak at Cannabis Industry Event in Phoenix Arizona $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 11:53 AM on Wednesday, February 12th, 2020
  • Announced that its Sun Valley Health division will be a lead sponsor at the Arizona Cannabis Industrial Market Place expo February 13th & 14th, 2020 at the Phoenix Convention Center.
  • In addition, the Company will run an onsite Sun Valley Health POP-UP medical clinic, offering cannabis consultations, certifications and services by Sun Valley Health doctors.

EMPOWER CLINICS SUBSIDIARY SUN VALLEY HEALTH TO LEAD SPONSOR THE ARIZONA CANNABIS EXPO AND EMPOWER BOARD MEMBER ANDREJS BUNKSE TO SPEAK AT CANNABIS INDUSTRY EVENT IN PHOENIX ARIZONA

VANCOUVER B.C. FEBRUARY 12TH, 2020 – EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company”), a vertically integrated and growth-oriented CBD life sciences company is pleased to announce that its Sun Valley Health division will be a lead sponsor at the Arizona Cannabis Industrial Market Place expo February 13th & 14th, 2020 at the Phoenix Convention Center. In addition, the Company will run an onsite Sun Valley Health POP-UP medical clinic, offering cannabis consultations, certifications and services by Sun Valley Health doctors.

“Our Sun Valley Franchising team has toured the U.S. over the past six months sharing our Scientific Approach to Alternative Medicine.” Said Dustin Klein, SVP Business Development and Director. “Being the title sponsor for the Cannabis Industrial Market Place national tour has brought us tremendous opportunities from around the globe. The upcoming Arizona CIMP Expo gives us the opportunity to share our growth and recent success with our dedicated community of patients, advocates, and business partners.”

The Company is also pleased to announce that Andrejs Bunkse, a Company Director, will be participating as an expert panelist in the “Growing Your Business in the Cannabis Industry” – Fireside Chat hosted by Rebel Rock Accounting of Phoenix Arizona.

https://www.eventbrite.com/e/growing-your-business-in-the-cannabis-industry-fireside-chat-registration-89899753583

“Being an active participant in our industry is imperative to our growth, it provides us greater connections to patients, plus early access to trends and new developments that allow us to be progressive thought leaders” Said Steven McAuley, Chairman & CEO.  

“We are delighted to host this event, bringing together many of Arizona’s successful cannabis operators “ Said Melissa Diaz, CFO & Co-Founder of Rebel Rock. “Our women owned business is at the forefront in helping the cannabis industry become more mainstream and appealing to women consumers and entrepreneurs.” 

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.

ABOUT REBEL ROCK

Rebel Rock was founded in 2019 by three accomplished female entrepreneurs to fill a clear and vast void in the cannabis industry. Rebel Rock puts confidence in cannabis, by helping emerging cannabis companies manage all their accounting, tax and operational efficiency needs.   The Company offers customized cloud accounting solutions and business system implementations that provide peace of mind, streamlined operations and improved profitability.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:      Steven McAuley

                   CEO

                   [email protected]

                   604-789-2146

Investors:      Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Tags: , , , , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Subsidiary Sun Valley Health to Lead Sponsor the Arizona #Cannabis Expo and Empower Board Member Andrejs Bunkse to Speak at Cannabis Industry Event in Phoenix Arizona $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

PRIMO Nutraceuticals $PRMO.ca – Consumers Clamor for #CBD as More Novel Uses are Purported $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 1:15 PM on Tuesday, February 11th, 2020

SPONSOR:  PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

Consumers Clamor for CBD as More Novel Uses are Purported

  • CBD products overall are having a major impact on the global industry because they offer a number of therapeutic benefits without the psychoactive effects of THC
  • Currently, this segment of the cannabis industry is also gaining prevalence for its potential to treat serious medical conditions such as cancer, multiple sclerosis, Alzheimer’s, Parkinson’s, depression, and anxiety.

NEW YORK, Feb. 11, 2020 — Earlier in 2018, the Farm Bill restored industrial hemp to nationwide legal production for the first time since World War II. Removing hemp from the Controlled Substances Act of 1970 (CSA) also helped create a financial domino effect – eventually leading to mass-market retailers CVS Health, Rite Aid, and Walgreens Boots Alliance to carry hemp-CBD brands. Notably, cannabis-based oils have become widely popular because of their potent and immediate effects.

In fact, CBD products overall are having a major impact on the global industry because they offer a number of therapeutic benefits without the psychoactive effects of THC. Currently, this segment of the cannabis industry is also gaining prevalence for its potential to treat serious medical conditions such as cancer, multiple sclerosis, Alzheimer’s, Parkinson’s, depression, and anxiety. And as the U.S. hemp industry matures, it is expected to transition from being a seed, textile, and industrial product importer to a global exporter. And according to data compiled by Hemp Business Journal, a division of New Frontier Data, the total sales for the U.S. hemp industry totaled USD 820 Million in 2017. The research also suggests that the industry is expected to grow to USD 1.9 Billion by 2022 and at a CAGR of 14.4% during the 5-year period.

The 2018 Farm Bill, however, explicitly preserved the FDA’s authority to regulate products containing cannabis or cannabis-derived compounds under the FD&C Act and section 351 of the Public Health Service Act (PHS Act). This leaves a lot of uncertainties regarding which products can be sold legally. According to the FDA, it treats products containing cannabis or cannabis-derived compounds as it does any other FDA-regulated products – meaning they’re subject to the same authorities and requirements as FDA-regulated products containing any other substance.

This is true regardless of whether the cannabis or cannabis-derived compounds are classified as hemp under the 2018 Farm Bill. And despite the federal regulatory uncertainties, at least 70% of the 2019 U.S. hemp harvest is intended for extract production, with Colorado leading the nation in hemp cultivation and processing land area with over 80,000 acres reported.

“The 29 U.S. states reporting licensed hemp cultivation acreage total almost half a million acres in combined cultivation land area, which is a massive increase compared to 2018 figures of a total land area barely over 100,000 acres. While there continues to be uncertainty and a healthy amount of confusion around hemp cultivation for CBD production, it is clear that demand is nonetheless continuing to rise across the U.S.,” noted Giadha Aguirre de Carcer, New Frontier Data CEO and Founder. “As states issue more licenses, consumer demand increases, and mass-market retailers such as CVS and Walgreens continue to expand their own product offerings, we expect the FDA may be forced to provide further regulatory clarifications sooner rather than later.”

Source: https://www.prnewswire.com/news-releases/consumers-clamor-for-cbd-as-more-novel-uses-are-purported-301002483.html

Tags: , , , ,
Posted in PRIMO Nutraceuticals Inc. | Comments Off on PRIMO Nutraceuticals $PRMO.ca – Consumers Clamor for #CBD as More Novel Uses are Purported $CROP.ca $VP.ca NF.ca $MCOA

Empower Clinics $CBDT.ca Announces Strong Start to The Year with January 2020 Patient Visits Increasing by 188% $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 6:31 AM on Tuesday, February 11th, 2020
  • Announced that patient visits in corporate clinics increased by 188% in January 2020 versus the same period in 2019, with total patient visits of 1,750 in January 2020 compared to 607 in January 2019.

VANCOUVER, BC /February 11, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company is pleased to announce that patient visits in corporate clinics increased by 188% in January 2020 versus the same period in 2019, with total patient visits of 1,750 in January 2020 compared to 607 in January 2019.

“January patient volumes were strong, setting the stage for potentially record first quarter patient visits, that are always focused on the patient experience, it’s a competitive advantage and I continue to be impressed with how our team members care for each and every patient they see.” said Steven McAuley, Chairman & CEO of Empower. “Looking forward, we are excited for our next franchise signings and the expansion of our product lines, adding to the in-clinic retail experience we are building.”

The Company utilizes it’s technology platform to communicate with patients by text message, email and call center ensuring appointments are confirmed and expected patient visits take place as planned.

The Company’s Sun Valley Health division also completed the set up and build out of it’s retail product counter and sales areas in it’s Tucson, AZ location, to showcase it’s CBD product line with over 50 unique SKU’s. Patients and customers can purchase product in clinic locations or online at www.sunvalleyhealth.com.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

CEO

[email protected]

604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , , , , , , ,
Posted in Empower Clinics Inc., Featured | Comments Off on Empower Clinics $CBDT.ca Announces Strong Start to The Year with January 2020 Patient Visits Increasing by 188% $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

NORTHBUD $NBUD.ca – Everything Canadians need to know about Legalization 2.0 $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 3:51 PM on Monday, February 10th, 2020

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

Everything Canadians need to know about Legalization 2.0

  • Edibles, extracts, topicals, and vapes are finally legal in Canada. Billed as Legalization 2.0, the regulations came into effect on October 17, 2019 and products have slowly begun to trickle onto the market ever since.

By Leafly Canada Staff

Edibles, extracts, topicals, and vapes are finally legal in Canada. Billed as Legalization 2.0, the regulations came into effect on October 17, 2019 and products have slowly begun to trickle onto the market ever since.

From how to consume, to what to consume, here’s everything Canadians need to know about Legalization 2.0.

Edibles 101

Cannabis-infused edibles are now available for sale through licensed retailers in Canada, though there are strict rules around marketing and dosing, including a limit of 10 mg of THC per packaged item.  Edibles in the form of food products, lozenges, and beverages can produce effective, long-lasting, and safe experiences. These forms of cannabis can also produce unpredictable effects that may feel like overdose symptoms. The difference is, of course, the dose, although it’s worth noting that while consuming too much can feel very unpleasant, no one has ever died from it.

It can take anywhere from 30 minutes to four hours for an edible to fully kick in. Health Canada suggests that adults who use cannabis, regardless of how they consume it, shouldn’t combine it with alcohol, nicotine or other drugs.

Source: https://www.leafly.com/news/strains-products/legalization-2-0-guide-canada

Tags: , , , , , , , ,
Posted in North Bud Farms Inc | Comments Off on NORTHBUD $NBUD.ca – Everything Canadians need to know about Legalization 2.0 $CGC $ACB $APH $CRON.ca $OGI.ca

PRIMO Nutraceuticals Inc. $PRMO.ca – #CBD’s Touted Therapeutic Benefits Help Loosen Regulatory Constraints $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 12:10 PM on Monday, February 10th, 2020

SPONSOR:  PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

CBD’s Touted Therapeutic Benefits Help Loosen Regulatory Constraints

  • Global cannabidiol market is expected to reach USD 9.69 Billion by 2025 while registering a CAGR of 32.6% during the forecast period.

NEW YORK, Feb. 10, 2020 – Most regions that have approved medical cannabis typically see doctors prescribe CBD-based medications to their patients. CBD, or cannabidiol, is a derivative of the hemp plant, yet is unlike its counterpart, THC, which is derived from the marijuana plant. Nowadays, the FDA acknowledges that CBD can possibly become a legitimate alternative medical treatment to a number of traditional therapeutics, further highlight the health benefits associated with the compound. However, the agency is requiring researchers to provide more data on the efficacy of CBD in order for CBD to become an approved medicinal treatment, prompting them to conduct large-scale clinical trials. “As legislation expands rapidly worldwide, the volume of efficacy data is growing, as are legitimate clinical trial studies,” says Liam McGreevy, Chief Executive Officer of Ethnopharm, a European cannabis company specializing in genetics and distribution, “This data will enable us to better understand the effects of the various cannabinoids and terpenes, their synergistic effect and how their impact links to the individual’s genetics or biomarkers.

This data is key to understanding the most effective combinations and strengths for various conditions, moving towards targeted personalized medicines.” And according to data compiled by Grand View Research, the global cannabidiol market is expected to reach USD 9.69 Billion by 2025 while registering a CAGR of 32.6% during the forecast period. Global Payout, Inc. (OTC: GOHE), Auxly Cannabis Group Inc. (OTC: CBWTF), Puration Inc. (OTC: PURA), Green Organic Dutchman Holdings Ltd. (OTC: TGODF), Liberty Health Sciences Inc (OTC: LHSIF)

As the cannabis industry continues to develop, lawmakers and federal agencies are actively working towards expanding the market. Recently, the U.S. Department of Agriculture (USDA) provided an update on its interim final rule process for hemp. According to the USDA, hemp production in the U.S. has seen a resurgence in the last five years; however, it remains unclear whether consumer demand will meet the supply. High prices for hemp, driven primarily by demand for use in producing CBD, relative to other crops, have also driven increases in planting. As such, producer interest in hemp production is largely driven by the potential for high returns from sales of hemp flowers to be processed into CBD oil.

And after extensive consultation with the Attorney General, the USDA issued the following interim final rule to establish the domestic hemp production program and to facilitate the production of hemp, as set forth in the 2018 Farm Bill: The USDA upholds the 0.3% threshold as out of its jurisdictional hands as written into the law. Furthermore, the lack of remedies for testing noncompliance raised suggestions that farmers be allowed to ship to processors who could remove the THC to keep the crop viable. Another subject of worry was the requirement (as described in the Federal Register) that laboratories be certified by the Drug Enforcement Administration (DEA), and crops tested within 15 days prior to harvest. Yet, by the end of January, only 44 labs existed to support more than 16,000 licensed farmers. Accordingly, the industry expects to remain bureaucratically constrained yet again after other fundamental supply-chain bottlenecks limited output and producers’ ability to bring their crops to market.

Source: https://www.prnewswire.com/news-releases/cbds-touted-therapeutic-benefits-help-loosen-regulatory-constraints-301001669.html

Tags: , , , , ,
Posted in PRIMO Nutraceuticals Inc. | Comments Off on PRIMO Nutraceuticals Inc. $PRMO.ca – #CBD’s Touted Therapeutic Benefits Help Loosen Regulatory Constraints $CROP.ca $VP.ca NF.ca $MCOA

CLIENT FEATURE: NORTHBUD $NBUD.ca Multinational #cannabis company laying the foundation to aggressively pursue the greatest recreational markets $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 2:32 PM on Tuesday, February 4th, 2020

Salinas greenhouse facility is currently operating 60,000 sq. ft. licensed canopy and contains ample room for expansion. The facility is also licensed for manufacturing and for distribution.

  • In late December completed first harvest at Salinas, California cultivation facility.
  • Harvested 2,687 plants that were included in the acquisition of the Qlora Group.
  • Anticipates completing testing and sale of the product in late January 2020, which will represent the first revenue generated by the Company in California.
  • Also completed an in-depth review and analysis of both the infrastructure and cultivation practices and will be implementing significant efficiencies over the course of the next four harvests.
  • Anticipates continual harvests of 2,000-3,000 plants every 25 days, with quality and yield improving with each harvest.
  • Product will be sold via wholesale agreements to existing Qlora clients in the interim as company prepares for the launch of NORTHBUD branded flower products in California in the third quarter of 2020. 

Cannabis Production Facility in Reno, Nevada

Assumed control of Nevada operation licensed for cultivation, manufacturing and distribution throughout the state.

  • Announced the completion of the first harvest of approximately 175 indoor grown plants
  • Upon the completion of testing and processing, the product will be distributed as NORTHBUD flower, pre-rolls and infused pre-rolls into selected Nevada dispensaries.
  • The launching of NORTHBUD branded products into Nevada marks a significant milestone for the Company.

Request for Outdoor Cultivation License:

  • In the context of a regular follow-up communication with Health Canada, representatives of the Company received verbal feedback that the application review is complete and the reviewers do not have any more questions
  • Subject to the re-submission of a required foreign police certificate related to one of the foreign directors of the Company, the Company will be in the final queue for receiving its licence.
  • The Company is confident that it will be able to file the certificate promptly; however, there can be no assurance as to the exact timing of the issuance of the licence by Health Canada or whether the Company will receive any final request from Health Canada.

FULL DISCLOSURE: NORTHBUD is an advertising client of AGORA Internet Relations Corp.

Tags: , , , , , , , ,
Posted in AGORACOM Client Feature, All Recent Posts, North Bud Farms Inc | Comments Off on CLIENT FEATURE: NORTHBUD $NBUD.ca Multinational #cannabis company laying the foundation to aggressively pursue the greatest recreational markets $CGC $ACB $APH $CRON.ca $OGI.ca

Spyder $SPDR.ca Announces Canceling of the Non-Brokered Financing, Secures $442,000 Bridge Loan from Management and Insiders and Appoints New Board Member $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:52 AM on Monday, February 3rd, 2020
  • Cancelled the previously announced (January 13, 2020) non-brokered private placement of senior secured convertible debentures in the aggregate principal amount of up to $1,500,000.

Vaughan, Ontario–(February 3, 2020) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“) would like to announce that it has cancelled the previously announced (January 13, 2020) non-brokered private placement of senior secured convertible debentures in the aggregate principal amount of up to $1,500,000.

BRIDGE LOAN SECURED

To ensure its short-term working capital needs are covered, Spyder has secured bridge loans in the amount of $442,000 provided primarily by management and insiders in the Company. The bridge loan will have the following attributes. The term matures on July 25, 2020, bears interest at 12% per annum payable monthly in arrears and Spyder may repay all or a portion there-on at any time during the period. To secure the bridge loans, Spyder granted a security interest over all of the personal property, assets and undertakings of Spyder.

“Securing a bridge loan for nearly half a million dollars largely from management and insiders shows confidence in Spyder’s ability to execute on its business model. We are excited to begin this next phase in Spyder’s development,” says Dan Pelchovitz, CEO of Spyder.

APPOINTMENT OF NEW BOARD MEMBER

In addition, Spyder is pleased to announce that Mr. Ben Leung has been appointed as a director. Ben is an accountant with over 28 years of financial accounting and management experience in both private industry and public practice. He is currently the Chief Financial Officer of Cultivate Capital Corp., a company investing and operating in the cannabis and hemp industry throughout North America. Over the past 2 years, Ben has acquired strong working knowledge of this industry and was responsible for leading strategic discussions, acquisitions, budgeting, financing, financial reporting and internal controls. Most recently, Ben was the controller, and then promoted to CFO of QE2 Acquisition Corp. He served a critical role in getting the corporation listed on the TSXV. His experience includes financial reporting, taxation, risk management, human resources and corporate governance. Prior to that, he was a senior manager with a Calgary based accounting firm and focused on the audit and assurance department. He has held controllership positions with publicly listed companies in the pharmaceutical, oil and gas, and manufacturing industries.

The Company would also like to announce the resignation of Mike Lerner from its Board of directors. The Company would like to thank Mr. Lerner for his time and commitment during his tenure on the Board.

MI 61-101 DISCLOSURE

Several directors and insiders as defined in Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101“), participated in the bridge loans, either directly or indirectly, therefore the bridge loans constitute a “related party transaction” within the meaning of MI 61-101. In its consideration and approval of the bridge loans, the board of directors of the Company determined that the bridge loans are exempt from the formal valuation and minority approval requirements of MI 61-101 on the basis that the fair market value of loans to related parties does not exceed 25% of the market capitalization of the Company, in accordance with Sections 5.5 and 5.7 of MI 61-101.

The Company did not file a material change report more than 21 days before the closing of the bridge loans as the details of the bridge loans, and the confirmation of insider participation in the bridge loans, was not definitively known to the Company until the date of the closing of the bridge loans and the board of directors determined that it was in the best interests of the Company to close the transaction as soon as practicable.

About Spyder Cannabis Inc.

Spyder is a CBD and Cannabis retailer that operates in jurisdiction where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of CBD in the United States, the second is the sale of smoking cessation and cannabis products in Ontario; and the third is the sale of cannabis products in Alberta.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities laws (“forward-looking statements”). Forward- looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

For more information, please contact:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer Telephone: 1.888.504.7737
Email: [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52035

Tags: , , , , , , ,
Posted in Spyder Cannabis Inc. | Comments Off on Spyder $SPDR.ca Announces Canceling of the Non-Brokered Financing, Secures $442,000 Bridge Loan from Management and Insiders and Appoints New Board Member $CGC $ACB $APH $CRON.ca $OGI.ca

NORTHBUD $NBUD.ca – Canada’s #Marijuana Sales Top $100 Million in a Month for the First Time $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 5:40 PM on Tuesday, January 28th, 2020

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

  • Aside from the fact that cannabis sales hit a new all-time high in November — something not unexpected given that the Canadian pot industry is still ramping up — what really stood out is that monthly sales finally eclipsed $100 million (that’s U.S. dollars). 

By: Sean Williams

It’s pretty incredible what a difference a year can make.

At this time last year, cannabis stocks were flying high, and the expectation had been that most brand-name companies would push toward recurring profitability by the end of the year. Of course, hindsight being what it is, we know this didn’t happen. High tax rates in select U.S. states, persistent supply issues in Canada, and a resilient black market weighed heavily on the cannabis industry in 2019 and pushed a number of popular pot stocks to two-year lows.

However, there may be light at the end of the tunnel.

Image source: Getty Images.

Canadian weed sales just hit a monthly milestone

Late last week, Statistics Canada released its monthly retail trade sales data for November. Since the marijuana industry is tightly regulated, but nonetheless legal, licensed cannabis store data is included in this monthly report. Aside from the fact that cannabis sales hit a new all-time high in November — something not unexpected given that the Canadian pot industry is still ramping up — what really stood out is that monthly sales finally eclipsed $100 million (that’s U.S. dollars). 

Here’s a snapshot of how licensed cannabis store sales have progressed since adult-use weed hit dispensary shelves on Oct. 17, 2018 (data is reported in Canadian dollars (CA$), with parenthesis featuring U.S. dollar equivalency).

  • October (2018): CA$53.68 million ($40.83 million)
  • November (2018): CA$53.73 million ($40.87 million)
  • December (2018): CA$57.34 million ($43.61 million)
  • January: CA$54.88 million ($41.74 million)
  • February: CA$51.66 million ($39.29 million)
  • March: CA$60.94 million ($46.35 million)
  • April: CA$74.58 million ($56.73 million)
  • May: CA$85.81 million ($65.27 million)
  • June: CA$91.46 million ($69.56 million)
  • July: CA$107.36 million ($81.66 million)
  • August: CA$125.95 million ($95.8 million)
  • September: CA$122.93 million ($93.5 million)
  • October: CA$128.98 million ($98.1 million)
  • November: CA$135.75 million ($103.25 million)

It took more than a year, but November featured more than $103 million in sales for Canada, a market that Wall Street foresees generating $5 billion in annual sales by 2024. As a whole, the Canadian marijuana market has generated $916.6 million in revenue since sales commenced on Oct. 17, 2018. This makes it very likely that Canada surpassed $1 billion in aggregate pot sales since launch in December, but we’ll have to wait a month to confirm.

Image source: Getty Images.

Here’s why Canadian cannabis sales could make a major leap forward in 2020

The hope, among both Wall Street and investors, is that this uptick in sales is really just the tip of the iceberg. Two key changes in the cannabis market are expected to improve consumer demand and relieve a lot of the supply bottlenecks that’ve hindered pot sales to this point.

The first is the launch of high-margin derivative products, which kicked off in mid-December. Derivatives are non-dried flower products, such as vapes, edibles, infused beverages, topicals, and concentrates. Not only do derivatives offer a new means of consumption that doesn’t, necessarily, require smoking cannabis, but they’re significantly more attractive to a younger generation of users who have shown a greater willingness to try or buy these higher-margin consumption alternatives.

According to investment bank Cowen Group, half of all U.S. pot sales are expected to be generated from derivatives, with dried flower and pre-rolled cannabis making up the other 43% and 7%, respectively. If these figures translate similarly in Canada, then the launch of derivatives should begin to put some pep in grower’s step by midyear, or maybe even sooner.

The other major catalyst is the long-awaited dispensary license reform being undertaken in Ontario, the country’s largest province by population. Having previously worked with a lottery system, Ontario, home to 38% of Canada’s residents, only opened 24 cannabis retail stores as of the one-year anniversary of recreational weed sales. This created few channels for legal product to reach consumers and allowed the black market to thrive.

Moving forward, Ontario has plans to issue dispensary licenses in a more traditional fashion. Licenses should start being issued by no later than April, with the expectation of 20 (or more) stores opening each month. By year’s end, provincial regulators hopes to have around 250 open locations, representing about a 10-fold increase from where it began the year.

Image source: Getty Images.

Source: https://www.fool.com/investing/2020/01/28/canadas-marijuana-sales-top-100-million-in-a-month.aspx

Tags: , , , , , , , ,
Posted in North Bud Farms Inc | Comments Off on NORTHBUD $NBUD.ca – Canada’s #Marijuana Sales Top $100 Million in a Month for the First Time $CGC $ACB $APH $CRON.ca $OGI.ca

INTERVIEW: After Building 165,000 Patients, Empower $CBDT.ca Clinics Sells 1st #CBD Clinic Franchise $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 8:47 AM on Tuesday, January 28th, 2020

Tags: , , , , , , ,
Posted in AGORACOM Via Satellite, Empower Clinics Inc. | Comments Off on INTERVIEW: After Building 165,000 Patients, Empower $CBDT.ca Clinics Sells 1st #CBD Clinic Franchise $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

« Older Entries
Newer Entries »